Target intelligence / Profile preview

Hen egg-white lysozyme aggregation interface

Molecular classification
Enzyme (Glycosidase), Other (Protein aggregation interface)
01

Overview

Hen egg-white lysozyme is a small, stable enzyme (129 amino acids) that hydrolyzes β(1→4) glycosidic bonds between N-acetylmuramic acid and N-acetylglucosamine in bacterial cell walls, thereby conferring antibacterial activity. The enzyme is highly abundant in bird egg whites and secretions like tears and saliva, serving an important defensive role in innate immunity. The aggregation interface refers to structural regions of lysozyme that interact during protein aggregation under destabilizing conditions—such as elevated temperature or altered pH—leading to the formation of amyloid-like fibrils. Aggregation studies are primarily biophysical and relate to understanding protein misfolding, not to drug targeting. If your intent is to catalog molecular targets for drug development or clinical applications, revert to "Hen egg-white lysozyme" (HEWL) rather than the aggregation interface, as only the enzyme has established classification, function, and aliases. The aggregation interface is a laboratory research concept and not a canonical target.

Other names
LysozymeMuramidaseHEWL
02

Mechanism of action

Not applicable for aggregation interface. Lysozyme enzyme itself cleaves β(1→4) glycosidic bonds in peptidoglycans

03

Biological functions

Hydrolysis of bacterial cell wall polysaccharidesComponent of the innate immune systemProtein aggregation under destabilizing conditions
04

Disease associations

Infection (antibacterial function)Other (used as model protein in aggregation, amyloid-like studies)
05

Safety considerations

For pharmaceutical protein drugs, aggregation can present immunogenicity concerns. HEWL is not used therapeutically, so safety challenges aren't clinically relevant; protein aggregation is generally undesirable due to potential toxicity in other systems
06

Interacting drugs

None established specific to the aggregation interface. Lysozyme activity can be inhibited by saccharide analogs (e.g., NAG3 trisaccharide), but these inhibit the active site, not aggregation itself
07

Biomarkers

None established for the aggregation interface; lysozyme levels can be a general marker for infection or inflammation, but not for aggregation per se

Beyond the preview

Go deeper on Hen egg-white lysozyme aggregation interface.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hen egg-white lysozyme aggregation interface.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call